Kenneth E. Weg
Gründer bei Metamark Genetics, Inc.
Profil
Kenneth E.
Weg is the founder and currently holds the position of Chairman at Metamark Genetics, Inc. which was founded in 2007.
He was also the founder and held the position of Chairman at Clearview Projects, Inc. in 2010.
Additionally, Mr. Weg was the founder and served as an Independent Director at AVEO Pharmaceuticals, Inc. in 2012.
Mr. Weg's current job is as a Member at Harvard Partners Center for Genetics & Genomics.
Mr. Weg's former jobs include being Vice Chairman at Bristol Myers Squibb Co. from 1991 to 2001, Non-Executive Chairman at Millennium Pharmaceuticals, Inc. from 2001 to 2008, and Director at The Fox Chase Cancer Center.
He also served as an Independent Director at Karyopharm Therapeutics, Inc.Mr. Weg obtained an MBA from The Trustees of Columbia University in The City of New York in 1962.
He also completed his undergraduate degree at Dartmouth College in 1960.
Aktive Positionen von Kenneth E. Weg
| Unternehmen | Position | Beginn |
|---|---|---|
Metamark Genetics, Inc.
 Metamark Genetics, Inc. Medical/Nursing ServicesHealth Services Metamark Genetics, Inc. provides molecular diagnostics services. It develops prognostic and predictive diagnostic tests that will enable personalized treatment planning for cancer patients. It transforms cancer diagnosis and treatment by developing pioneering diagnostic products based on its prognosis determinants platform. The company was founded by Kenneth E. Weg, Raju S. Kucherlapati, David Rimm, Lynda Chin and Ronald A. DePinho in November 2007 and is headquartered in Waltham, MA. | Gründer | 01.11.2007 |
| Harvard Partners Center for Genetics & Genomics | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Kenneth E. Weg
| Unternehmen | Position | Ende |
|---|---|---|
| AVEO PHARMACEUTICALS, INC. | Gründer | 01.08.2013 |
| Clearview Projects, Inc. | Gründer | 01.01.2010 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Vorsitzender | 14.05.2008 |
| BRISTOL-MYERS SQUIBB COMPANY | Direktor/Vorstandsmitglied | 01.02.2001 |
| KARYOPHARM THERAPEUTICS INC. | Direktor/Vorstandsmitglied | - |
Ausbildung von Kenneth E. Weg
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| Dartmouth College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Metamark Genetics, Inc.
Metamark Genetics, Inc. Medical/Nursing ServicesHealth Services Metamark Genetics, Inc. provides molecular diagnostics services. It develops prognostic and predictive diagnostic tests that will enable personalized treatment planning for cancer patients. It transforms cancer diagnosis and treatment by developing pioneering diagnostic products based on its prognosis determinants platform. The company was founded by Kenneth E. Weg, Raju S. Kucherlapati, David Rimm, Lynda Chin and Ronald A. DePinho in November 2007 and is headquartered in Waltham, MA. | Health Services |
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
The Fox Chase Cancer Center
 The Fox Chase Cancer Center Hospital/Nursing ManagementHealth Services The Fox Chase Cancer Center owns and operates hospitals. It is an independent, non-profit institution that is engaged in cancer treatment, research and prevention services. The firm's staff provides consultations and treatment recommendations for different types of adult cancer. The company was founded in 1904 and is headquartered in Philadelphia, PA. | Health Services |
| Harvard Partners Center for Genetics & Genomics | |
| Clearview Projects, Inc. |
